Principal Investigator: Dr Harpal Randeva

Location: University Hospital Coventry and Warwickshire, with recruitment from UHCW, George Eliot and Warwick Hospitals as well as NHS Community Health Clinics and GP practices within Coventry and Warwickshire.

Enrolment: Period: October 2013 - December 2014

Participants: Women with PCOS

Study Details 

The Lipos (Liraglutide in PCOS) study has recently begun recruitment in the Coventry and Warwickshire area. Lipos is a prospective, randomised, double blind, placebo controlled study investigating the use of Liraglutide alongside Metformin SR to improve fertility and symptom control in women diagnosed with Polycystic Ovary Syndrome. The study is funded by Novonordisk, sponsored by the University of Warwick and hosted by UHCW.

The study aims to establish whether the combined use of Metformin SR and Liraglutide will improve menstrual regularity amongst women diagnosed with PCOS. Secondary outcome measures include improvements in other symptoms and effects of the condition including hirsutism, metabolic syndrome and difficulty controlling weight and acne.

We aim to enrol 106 participants, who will all receive Metformin SR, with randomisation leading to 50% receiving Liraglutide and 50% receiving a placebo. Participants will need to attend UHCW on a number of occasions (17) over a period of 62 weeks, with multiple data being collected by study clinicians at each visit to measure a wide range of metabolic and cardiovascular parameters. Potential participants should be over 18 and diagnosed with PCOS.  

If you would like to be involved, or for more information, please contact Dr Randeva email: harpal.randeva@warwick.ac.uk or the study nurse, Kay Webb, email: Kathryn.webb@uhcw.nhs.uk